BactiQuant (BACTIQ) H2 2024 earnings summary

Executive summary

• Revenue for 2024 was DKK 7.2 million, down from DKK 12.3 million in 2023, in line with revised guidance due to delayed large orders and focus on pilot projects expected to contribute in 2025 and beyond.

• EBITDA for 2024 was DKK -11.0 million, compared to DKK -9.5 million in 2023, also within the revised guidance.

• The company completed a capital increase in early 2025, raising DKK 14.3 million to support ongoing operations and growth.

Financial highlights

• Revenue: DKK 7.2 million (2023: DKK 12.3 million), a 42% decrease year-over-year.

• EBITDA: DKK -11.0 million (2023: DKK -9.5 million).

• Net result: DKK -13.7 million (2023: DKK -13.1 million).

• Recurring revenue from testkits remained stable at DKK 4.5 million.

• Cash position at year-end: DKK 0.85 million (2023: DKK 11.8 million).

Outlook and guidance

• 2025 revenue guidance: DKK 10–14 million.

• 2025 EBITDA guidance: DKK -8 to -11 million.

• Additional capital will be required in the first half of 2026 to support growth plans.